China BioMed Innovation & Investment Conference

Global Oncology Track

September 19, 2018 | Suzhou, China



CONFERENCE HOSTS

PhIRDA 中国药促会

HKEX 香港交易所

中国医疗器械行业协会 China Association for Medical Devices Industry

中國醫院協會 Chinese Hospital Association

ONCOLOGY TRACK HOSTS

National Foundation for Cancer Research

Research for a Cure

Asian Fund for Cancer Research Limited 亞洲癌症研究基金會有限公司

AGENDA

1st Half Moderator: NFCR President & Chief Operating Officer **Dr. Sujuan Ba**

08:30 – 08:40 1st Opening Remarks by **Dr. Ba**
08:40 – 08:50 2nd Opening Remarks by PhIRDA Executive President **Mr. Song Ruilin**
08:50 – 09:15 Keynote by former Cardinal Health (Fortune 500, # 14) Chairman & CEO **Mr. David Schlotterbeck**

Showcase Company Presentations:
09:15 – 09:40 Minneamrita Therapeutics Chief Scientific Officer **Dr. Ashok Saluja**
09:40 – 10:05 Sun BioPharma Chief Executive Officer **Mr. David Kaysen**
10:05 – 10:30 Immunicom Chief Executive Officer **Mr. Amir Jafri**
10:30 – 10:55 Geneius Biotechnology Chief Executive Officer **Dr. Alfred Slanetz**
10:55 – 11:05 Break

2nd Half Moderator: PhIRDA Senior Member and YuanMing Capital Managing Partner **Dr. Tina Yu**

Showcase Company Presentations (continued):
11:05 – 11:30 ORYX Chief Executive Officer **Dr. Bernard Huber**
11:30 – 11:55 Apricity Health Chief Executive Officer **Dr. Lynda Chin**
11:55 – 12:20 Rafael Pharmaceuticals Chief Executive Officer **Mr. Sanjeev Luther**

12:20 – 12:40 Closing Remarks and Presentation by NFCR Chief Strategy Officer **Dr. Michael Wang**

SPEAKER BIOGRAPHIES

Dr. Sujuan Ba

Dr. Sujuan Ba is the President and Chief Operating Officer of the National Foundation for Cancer Research. She has extensive experience in developing strategic alliances with academic leaders, industry executives and pharmaceutical policymakers, and has been actively involved in promoting and facilitating international collaboration to pioneer innovative cancer research. Dr. Ba is a co-founder of the AGILE Research Foundation and the International Cancer Impact Fund, and a founding board member of the Global Coalition for Adaptive Research, the organizing body leading the global implementation of GBM AGILE, a groundbreaking adaptive clinical trial initiative designed to produce new and better treatments for glioblastoma multiforme. She sits on the scientific advisory boards of Medelis, Inc. and Immunicom Inc., is an editorial board member of the *Chinese Journal of Cancer* and was named one of the "Top 300 Women Leaders in Global Health" in 2015 by the Swiss-based Graduate Institute of International and Development Studies' Global Health Programme. Dr. Ba received her B.S. in radiochemistry from Peking University and her Ph.D. in chemistry from the University of Pennsylvania.

SPEAKER BIOGRAPHIES

Dr. Tina Yu



Dr. Tina Yu is a managing partner with YuanMing Capital. She has more than fifteen years of professional experience working in both the life sciences and healthcare finance sectors. Dr. Yu has led YuanMing's investments into BeiGene, Ascentage Pharmaceuticals and Mevion Medical Systems, among others. Prior to her current role with the company, she worked as investment director for Vision Capital, a New York City-based investment management firm, where she was responsible for covering both the U.S. and China's biotechnology sectors. Before becoming an investor, Dr. Yu was a senior research scientist at Wyeth BioPharma, where she specialized in therapeutic protein development. She also worked for Fidelity, Morgan Stanley and Genzyme. Dr. Yu also founded Matching Capital Partners, providing cross-border consulting services in the life sciences industry. She holds a B.S. in biology from the University of Science and Technology of China, a Ph.D. in chemistry from Princeton University and an MBA from the Harvard Business School.

Dr. Michael Wang

Dr. Michael Wang is the chief strategy officer of the National Foundation for Cancer Research (NFCR). He is actively involved in developing strategic alliances and critical collaborations with international organizations in both academic and industrial communities, and working closely with technology transfer and intellectual property protection offices. Dr. Wang has extensive experience in scientific program management, due diligence and early-stage technology evaluation and development. He previously served as NFCR's Chief Science Officer, overseeing all aspects of the organization's cancer research programs and research initiatives across over 30 laboratories in universities, research institutes and teaching hospitals in the U.S., Germany and China. Before joining NFCR in 2002, Dr. Wang had worked at the University of Pennsylvania as a research fellow and at British Technology Group as a senior business development manager for its oncology and genomics/proteomics groups. He received his M.D. from the Second Military Medical College in Shanghai, China, his Ph.D. in molecular biology from Kyoto University, Japan, and his MBA from Penn State University .

COMPANY DESCRIPTIONS

Minneamrita Therapeutics LLC is a small molecule drug development bio-pharmaceutical company co-founded by Chief Executive Officer Mohana Velagapudi, M.D., and Chief Scientific Officer Ashok Saluja, Ph.D. MinnelideTM, a water-soluble prodrug of triptolide, was developed at the University of Minnesota and is the firm's lead compound. MinnelideTM has been patented worldwide and is licensed by Minneamrita. A Phase I study of intravenous MinnelideTM in patients with advanced gastrointestinal tumors has been completed. A Phase II international open label trial of intravenous MinnelideTM in patients with refractory pancreatic cancer is undergoing. Two additional Phase I multicenter open-label dose escalation and safety study of MinnelideTM oral capsules for solid tumors too are underway. And a Phase I study of MinnelideTM oral capsules in patients with advanced or refractory Acute myeloid leukemia will commence shortly. Preclinical studies are showing very promising results in various cancers and liver fibrosis (NASH), and orphan drug status has been granted for MinnelideTM in pancreatic and gastric cancers.

Sun BioPharma, a United States publicly traded company (OTCQB:SNBP), is a clinical stage drug developer which, together with its Australian subsidiary, has exclusively licensed the worldwide rights to a compound, SBP-101, from the University of Florida Research Foundation, Inc. SBP-101 is a proprietary polyamine analogue which exhibits an extraordinary specificity for the exocrine pancreas with therapeutic potential for both pancreatic ductal adenocarcinoma (PDA) and for a second potential indication for chronic and recurrent acute pancreatitis. Sun BioPharma has completed its Phase 1 Dose Escalation Safety Trial in stage four PDA patients who have failed at least one front line therapy and whose disease is progressing. The Maximum Tolerated Dose was determined in this study and the Data Safety Monitoring Board approved moving to a front line Phase 1a/1b trial on newly diagnosed, previously untreated PDA patients. First patients have been enrolled in this study on 13 June 2018. Sun BioPharma is seeking equity funding partners to complete the current Phase 1a/1b study and properly position the company for a pivotal trial for PDA.

Immunicom, Inc. has leveraged the latest, cutting-edge clinical research in immune regulatory pathways and their role in cancer and autoimmune disease to develop a revolutionary immunotherapy platform (Immunopheresis™) fortreating cancer and other terminal diseases through a BLOOD FILTERING DEVICE. The firm filters a patient's blood of "blocking proteins" released by cancer cells that suppress the immune system. Once these proteins are removed, the immune system naturally attacks the tumor and cancer. Immunicom is led by Amif Jafri, the former R&D head of Cardinal Health. The company's first target is Soluble tumor necrosis factor receptors (STNFr). In May 2018 the company received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Immunopheresis™ therapy. To achieve Breakthrough Device designation, a technology must demonstrate compelling potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases. In addition, there must be no FDA approved treatments presently available, or the technology must offer significant advantages over existing approved alternatives.

COMPANY DESCRIPTIONS

Geneius Biotechnology, Inc. is a private biopharmaceutical company run by Aldred Slanetz, Ph.D., the former CEO of bluebird bio (NASDAQ-traded; $8.3 billion market capitalization) focused on the discovery and clinical development of adoptive T cell therapy products that address the treatment of cancer and infections. The company has created a good manufacturing process, or GMP, for the production of T cells from peripheral blood for infusion into the patient, allowing for manufacturing at a price of 1/10th that of traditional CAR-T. Geneius's targeted DiversiTy™ platform is a novel ex vivo approach that re-educates T cells to become responsive to multiple, previously overlooked tumor antigens. Geneius's lead product candidate, GNS-TEBV-001, is currently in preclinical testing for EBV+, non-Hodgkin lymphoma, gastric and nasopharyngeal cancers. Geneius also has two additional products, GNS-TGBM-002 and GNS-TPC-003, in preclinical testing for glioblastoma and pancreatic cancer, respectively.

ORYX is a privately held German company that develops highly innovative translational immunotherapy projects in cancer indications with high unmet medical need. The firm develops promising projects from academia through clinical proof of concept trials before partnering for further clinical development and commercialization. ORYX has exclusive global licenses to three premier cancer immunotherapy projects of the German Cancer Research Center and the University of Heidelberg. These projects have been successfully developed by ORYX through clinical Phase I/IIa trials, which clearly demonstrated compelling safety and efficacy data. The lead project, ParvOryx, is an oncolytic parvovirus H1 (H-1PV) that infects and lyses a wide variety of human tumors. In clinical trials with recurrent glioblastoma and metastatic pancreatic cancer patients, respectively, ParvOryx showed positive results for safety and efficacy. Its other two projects, MicOryx and CicOryx, have also shown positive results in clinical trials. ORYX is seeking industry partners for further development of all three immunotherapy assets.

Apricity Health has harnessed knowledge and expertise of the world's experts in immune-oncology therapy to develop ApricityCare™, an intelligent and interactive care pathway that (1) empower patients and their clinical team with longitudinal monitoring and communication to facilitate early detection and timely intervention of immune-related adverse events (irAEs), and (2) disseminates best practices in irAE management by putting world-class expertise in the hands of practicing oncologists. AricityCare™ is built on a proprietary artificial intelligence platform that is modular, secure and HIPAA compliant. It is adaptable to evolving data types, IoT and cloud technologies, and translates curated expertise into decision support algorithms and digitized workflows to democratize best practices. In addition, it will capture longitudinal real-world efficacy and toxicity data to personalize management and inform R&D pipelines for safer and better therapies. With its first solution entering clinical trials in the U.S., Apricity is now exploring opportunities and seeking clinical partners to further develop and commercialize AricityCare™ in Asia.

COMPANY DESCRIPTIONS

Rafael Pharmaceuticals, Inc. is a pioneering, clinical-stage, metabolic oncology therapeutics company focused on transforming the lives of patients with hard to treat cancers by applying our deep understanding of unique bio-energetic processes specific to cancer. Our research in the field of altered cancer metabolism directed therapies has led to the discovery of novel, first-in-class drug candidates and drug delivery technologies that have the potential to revolutionize cancer treatment. Our primary objective is to produce highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues. By attacking regulatory processes that are unique to cancer and not found in healthy cells we aim to significantly improve the safety profile and efficacy of cancer treatment. CPI-613, the lead drug from our Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. CPI-613 is currently being evaluated in multiple Phase I, I/II, and II clinical studies as a single

LAST YEAR'S PRESENTERS

Stromatis PHARMA

eutropics PHARMACEUTICALS

IMMIX

INTERNATIONAL CANCER IMPACT FUND
Investment for Cure

InterLeukin COMBINATORIAL THERAPIES, INC

J.P.Morgan

InVaMet THERAPEUTICS

novocure™

NONPAREIL BIOTECHNOLOGIES LLC

ARRAY BIOPHARMA

NFCR AIM-HI PORTFOLIO COMPANIES

SILCSBIO FREE ENERGY BASED LIGAND DESIGN	Applying small-molecule derivatives of artemisinins to treat leukemia
Stromatis PHARMA	Advancing therapeutics that target stromal stellate cells for the treatment of cancer and fibrotic diseases
InterLeukin COMBINATORIAL THERAPIES, INC	Developing Cancer Terminator Viruses for the targeted therapy of a diverse array of aggressive tumor types
InVaMet THERAPEUTICS	Advancing therapeutics that target stromal stellate cells for the treatment of cancer and fibrotic diseases
tvardi THERAPEUTICS	Validating potential inhibitors of a protein, STAT-3, known to be associated with multiple cancers
ONCOKIDS BIOSCIENCES	Discovering novel biomarkers to repurpose and develop new drugs for pediatric cancer
NONPAREIL BIOTECHNOLOGIES LLC	Converting oncology laboratory achievements into commercial products with market demands and regulatory approvals

Thank You for Attending the 2018 Oncology Track!!